- Home
- MAX vs MLYS Comparison
MAX vs MLYS Comparison
Compare MAX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- MLYS
- Stock Information
- Founded
- MAX 2014
- MLYS 2019
- Country
- MAX United States
- MLYS United States
- Employees
- MAX N/A
- MLYS N/A
- Industry
- MAX Industrial Machinery/Components
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- MAX Industrials
- MLYS Health Care
- Exchange
- MAX Nasdaq
- MLYS Nasdaq
- Market Cap
- MAX 551.1M
- MLYS 890.6M
- IPO Year
- MAX 2020
- MLYS 2023
- Fundamental
- Price
- MAX $13.39
- MLYS $38.25
- Analyst Decision
- MAX Strong Buy
- MLYS Strong Buy
- Analyst Count
- MAX 6
- MLYS 6
- Target Price
- MAX $18.25
- MLYS $42.60
- AVG Volume (30 Days)
- MAX 631.7K
- MLYS 2.6M
- Earning Date
- MAX 10-29-2025
- MLYS 11-10-2025
- Dividend Yield
- MAX N/A
- MLYS N/A
- EPS Growth
- MAX N/A
- MLYS N/A
- EPS
- MAX N/A
- MLYS N/A
- Revenue
- MAX $1,075,712,000.00
- MLYS N/A
- Revenue This Year
- MAX $28.71
- MLYS N/A
- Revenue Next Year
- MAX $9.61
- MLYS N/A
- P/E Ratio
- MAX N/A
- MLYS N/A
- Revenue Growth
- MAX 116.58
- MLYS N/A
- 52 Week Low
- MAX $7.33
- MLYS $8.24
- 52 Week High
- MAX $20.91
- MLYS $39.20
- Technical
- Relative Strength Index (RSI)
- MAX 54.71
- MLYS 59.86
- Support Level
- MAX N/A
- MLYS $35.00
- Resistance Level
- MAX $13.28
- MLYS $39.20
- Average True Range (ATR)
- MAX 0.51
- MLYS 2.47
- MACD
- MAX -0.31
- MLYS -1.22
- Stochastic Oscillator
- MAX 98.93
- MLYS 96.79
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.